Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)

• Main Author: Moreira, Rodrigo Oliveira
• Publication Date: 2023
• Other Authors: Valerio, Cynthia Melissa, Villela-Nogueira, Cristiane Alves, Cercato, Cintia, Gerchman, Fernando, Lottenberg, Ana Maria Pita, Godoy-Matos, Amélio Fernando, Oliveira, Ricardo de Andrade, Mello, Carlos Eduardo Brandão, Álvares-Da-silva, Mário Reis, Leite, Nathalie Carvalho, Cotrim, Helma Pinchemel, Parisi, Edison Roberto, Silva, Giovanni Faria [UNESP], Miranda, Paulo Augusto Carvalho, Halpern, Bruno, Oliveira, Claudia Pinto
• Format: Article
• Language: eng
• Source: Repositório Institucional da UNESP
• Download full: http://dx.doi.org/10.20945/2359-4292-2023-0123; https://hdl.handle.net/11449/301712
• topic: Clinical guidelines; metabolic dysfunction-associated steatotic liver disease; non-alcoholic fatty liver disease; obesity; overweight

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on NAFLD. In the absence of studies on a certain topic or when the quality of the study was not adequate, the opinion of experts was adopted. Classes of Recommendation and Levels of Evidence were determined using prespecified criteria. Results: Based on the literature review, 48 specific recommendations were elaborated, including 11 on screening and diagnosis, 9 on follow-up, 14 on nonpharmacologic treatment, and 14 on pharmacologic and surgical treatment. Conclusions: A literature search allowed the development of evidence-based guidelines on the screening, diagnosis, treatment, and follow-up of MASLD in individuals with overweight or obesity.